{"gene":"SNTB2","run_date":"2026-06-10T07:46:37","timeline":{"discoveries":[{"year":1994,"finding":"SNTB2 (EST25263/basic A1 isoform) encodes a 59-kDa dystrophin-associated protein (DAP) that is part of the membrane cytoskeleton complex in muscle; it was isolated as a distinct syntrophin isoform and mapped to chromosome 16, establishing it as a component of the dystrophin-associated protein complex.","method":"cDNA cloning, partial peptide sequencing of purified DAP complex, EST database comparison, chromosomal mapping","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — protein purification and peptide sequencing identified the protein as a DAP complex member; single study but multiple orthogonal methods (biochemical purification, cloning, mapping)","pmids":["8183929"],"is_preprint":false},{"year":2015,"finding":"SNTB2 binds to the α1D-adrenergic receptor (ADRA1D) through a C-terminal PDZ ligand interaction, ensuring receptor plasma membrane localization and G-protein coupling. Syntrophins (SNTA, SNTB1, SNTB2) did not interact with any of 22 other tested GPCRs containing Type I PDZ ligands, indicating specificity for ADRA1D.","method":"TAP/MS proteomic analysis, biochemical assays, dynamic mass redistribution analysis","journal":"Cell discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — TAP/MS plus dynamic mass redistribution, single lab, multiple orthogonal methods confirming PDZ-mediated interaction and functional consequence","pmids":["26617989"],"is_preprint":false},{"year":2013,"finding":"The C-terminus of adiponectin receptor 1 (AdipoR1) contains a class I PDZ-binding motif that interacts with SNTB2, identified by yeast two-hybrid screening of a liver library. However, AMPK and p38 MAPK phosphorylation downstream of AdipoR1 was not blocked in SNTB2-deficient mice, and AdipoR1 protein levels were normal in SNTB2 knockout mice, indicating SNTB2 is not required for AdipoR1 signaling or stability in liver.","method":"Yeast two-hybrid, PDZ-domain array, immunofluorescence colocalization, knockout mouse studies","journal":"Experimental and molecular pathology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — yeast two-hybrid and PDZ array identify interaction; functional consequence tested in KO mice by multiple readouts, single lab","pmids":["23860432"],"is_preprint":false},{"year":2013,"finding":"SNTB2 expression is significantly upregulated in radioresistant H460R lung cancer cells; siRNA-mediated knockdown of SNTB2 sensitized H460, H460R, and H1299 cells to ionizing radiation, establishing a functional role for SNTB2 in radioresistance.","method":"Microarray gene expression profiling, siRNA knockdown, clonogenic survival assay, Western blot","journal":"Genomics & informatics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single siRNA knockdown approach with clonogenic assay; no mechanistic pathway placed","pmids":["24465237"],"is_preprint":false},{"year":2018,"finding":"SNTB2 forms a protein complex with utrophin in adipocytes (co-immunoprecipitation). SNTB2 protein levels are strongly diminished when utrophin is knocked down. Knockdown of either utrophin or SNTB2 enhances lipid droplet (LD) growth during adipogenesis without affecting adipogenic transcription factors (C/EBPα, SREBP) or lipolysis, placing SNTB2 in a utrophin-dependent pathway that restrains LD expansion.","method":"Co-immunoprecipitation, siRNA knockdown, lipid droplet size measurement, lipolysis assay, immunofluorescence localization","journal":"Molecular and cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal complex identified by Co-IP, functional consequence shown by KD with specific readout (LD size), single lab but multiple orthogonal methods","pmids":["30014220"],"is_preprint":false},{"year":2018,"finding":"In adipocytes with SNTB2 knockdown, antilipolytic activity of insulin is enhanced (insulin more effectively suppresses lipolysis), while basal and stimulated lipolysis rates and Akt phosphorylation are normal, indicating SNTB2 modulates a specific arm of insulin signaling related to lipolysis suppression.","method":"siRNA knockdown, lipolysis assay, Western blot for phospho-Akt","journal":"Molecular and cellular biochemistry","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single knockdown method; limited mechanistic depth beyond the phenotypic observation","pmids":["30014220"],"is_preprint":false},{"year":2018,"finding":"In fibroblasts, SNTB2 localizes to filamentous and vesicular structures that are distinct from beta-actin, alpha-tubulin, endoplasmic reticulum, early endosomes, lysosomes, and mitochondria, indicating a unique subcellular compartmentalization.","method":"Immunofluorescence colocalization in fibroblasts","journal":"Molecular and cellular biochemistry","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single immunofluorescence study, no functional consequence directly linked to localization","pmids":["30014220"],"is_preprint":false},{"year":2015,"finding":"In alpha/beta2-syntrophin double-knockout (SNTA/B2-/-) mice, hepatic SR-BI protein is strongly reduced. This reduction is associated with increased phosphorylated ERK2 in liver, and pharmacological blockade of ERK activity upregulates SR-BI, indicating that SNTB2/SNTA loss elevates MAPK/ERK activity which in turn destabilizes SR-BI. Direct siRNA knockdown of SNTB2 alone in hepatocytes did not reduce SR-BI, suggesting the effect is indirect or requires combined loss of both syntrophins.","method":"Knockout mouse studies (DKO), ERK inhibitor treatment, siRNA knockdown in hepatocytes, Western blot","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout plus pharmacological intervention plus cell-based KD, multiple orthogonal methods; single lab","pmids":["25625330"],"is_preprint":false},{"year":2019,"finding":"SNTB2-deficient mice on high-fat diet display reduced adiposity and adipocyte hypertrophy, with diminished caveolin-1 protein and collagen mRNA levels in white adipose tissue, enhanced fatty acid clearance in the fed state, and reduced systemic glucose. This places SNTB2 as a regulator of adipocyte size, caveolin-1 expression, and postprandial lipid metabolism in vivo.","method":"SNTB2 knockout mouse, high-fat diet challenge, histology, Western blot, serum metabolite measurements","journal":"Cellular physiology and biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo knockout with multiple metabolic and molecular readouts; single lab","pmids":["30990585"],"is_preprint":false}],"current_model":"SNTB2 is a PDZ domain-containing scaffold/adaptor protein that is a component of the dystrophin-associated protein complex; it binds the α1D-adrenergic receptor C-terminal PDZ ligand to ensure plasma membrane localization and G-protein coupling, interacts with utrophin in adipocytes to restrain lipid droplet expansion, binds the AdipoR1 C-terminus (though this interaction is dispensable for AdipoR1 signaling in liver), regulates adipocyte size and caveolin-1 levels in vivo, modulates insulin's antilipolytic activity, and indirectly influences hepatic SR-BI stability through control of ERK activity, with additional evidence for a role in cellular radioresistance."},"narrative":{"mechanistic_narrative":"SNTB2 is a PDZ domain-containing syntrophin that acts as a membrane-associated scaffold/adaptor, originally identified as a 59-kDa component of the dystrophin-associated protein complex of the muscle membrane cytoskeleton [PMID:8183929]. Through its PDZ domain it engages the C-terminal PDZ ligands of specific membrane receptors: it binds the α1D-adrenergic receptor (ADRA1D) to ensure receptor plasma membrane localization and G-protein coupling, with selectivity for ADRA1D over other PDZ-ligand GPCRs tested [PMID:26617989], and it binds the C-terminus of adiponectin receptor 1 (AdipoR1), although this interaction is dispensable for AdipoR1 signaling and stability in liver [PMID:23860432]. SNTB2 partners with utrophin in a complex that restrains lipid droplet expansion during adipogenesis, and its stability depends on utrophin [PMID:30014220]. In vivo, SNTB2 regulates adipocyte size, caveolin-1 levels, and postprandial lipid and glucose metabolism [PMID:30990585], and it shapes hepatic SR-BI abundance indirectly by limiting ERK/MAPK activity, an effect that requires combined loss of SNTB2 and α-syntrophin [PMID:25625330].","teleology":[{"year":1994,"claim":"Established the molecular identity of SNTB2 by showing it is a distinct syntrophin isoform belonging to the dystrophin-associated protein complex of the muscle membrane cytoskeleton.","evidence":"cDNA cloning, peptide sequencing of purified DAP complex, and chromosomal mapping","pmids":["8183929"],"confidence":"Medium","gaps":["Does not define the binding partners engaged by its PDZ domain","No functional role assigned beyond complex membership"]},{"year":2013,"claim":"Tested whether SNTB2's PDZ interaction with AdipoR1 is functionally required, addressing whether SNTB2 acts as a signaling adaptor for adiponectin signaling.","evidence":"Yeast two-hybrid liver library screen, PDZ-domain array, and knockout mouse readouts of AMPK/p38 phosphorylation","pmids":["23860432"],"confidence":"Medium","gaps":["The biological consequence of the AdipoR1–SNTB2 interaction outside liver is undefined","No structural basis for the PDZ-ligand binding shown"]},{"year":2013,"claim":"Linked SNTB2 expression to a cellular phenotype by showing knockdown sensitizes lung cancer cells to radiation, implicating it in radioresistance.","evidence":"Microarray profiling, siRNA knockdown, and clonogenic survival assays in lung cancer lines","pmids":["24465237"],"confidence":"Low","gaps":["No mechanistic pathway connecting SNTB2 to the DNA damage or survival response","Single siRNA approach without rescue"]},{"year":2015,"claim":"Demonstrated PDZ-ligand-specific recruitment of the α1D-adrenergic receptor by SNTB2, establishing a defined receptor-scaffolding function controlling receptor membrane localization and coupling.","evidence":"TAP/MS proteomics, biochemical binding assays, and dynamic mass redistribution analysis with a panel of 22 control GPCRs","pmids":["26617989"],"confidence":"Medium","gaps":["Whether other syntrophin-binding receptors exist in vivo is unresolved","No structural model of the ADRA1D–SNTB2 PDZ interface"]},{"year":2015,"claim":"Revealed an indirect role for SNTB2 in hepatic SR-BI stability via ERK control, distinguishing combined syntrophin loss from single-gene knockdown.","evidence":"α/β2-syntrophin double-knockout mice, ERK inhibitor treatment, and hepatocyte siRNA knockdown with Western blot","pmids":["25625330"],"confidence":"Medium","gaps":["The molecular link between syntrophin loss and elevated ERK activity is not defined","Functional redundancy with α-syntrophin obscures the SNTB2-specific contribution"]},{"year":2018,"claim":"Placed SNTB2 in a utrophin-dependent pathway restraining lipid droplet growth and identified a specific modulation of insulin's antilipolytic arm in adipocytes.","evidence":"Reciprocal Co-IP, siRNA knockdown, lipid droplet sizing, lipolysis assays, and phospho-Akt Western blot","pmids":["30014220"],"confidence":"Medium","gaps":["The mechanism by which the utrophin–SNTB2 complex limits lipid droplet expansion is unknown","How SNTB2 selectively affects antilipolytic insulin signaling without altering Akt is unresolved"]},{"year":2019,"claim":"Defined SNTB2 as an in vivo regulator of adipocyte size, caveolin-1 expression, and postprandial lipid/glucose metabolism under dietary challenge.","evidence":"SNTB2 knockout mice on high-fat diet with histology, Western blot, and serum metabolite measurements","pmids":["30990585"],"confidence":"Medium","gaps":["The direct molecular target linking SNTB2 to caveolin-1 levels is not identified","Whether the metabolic phenotype derives from adipocyte-autonomous SNTB2 function is untested"]},{"year":null,"claim":"The unifying biochemical mechanism by which SNTB2's PDZ-mediated scaffolding controls receptor signaling, lipid droplet dynamics, and ERK activity across tissues remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural data on SNTB2 PDZ-ligand complexes","No single signaling pathway unifies its adrenergic, adiponectin, and metabolic roles","Tissue-specific contributions versus syntrophin redundancy not separated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,1,2,4]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1]}],"pathway":[],"complexes":["dystrophin-associated protein complex"],"partners":["ADRA1D","ADIPOR1","UTRN","SNTA1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13425","full_name":"Beta-2-syntrophin","aliases":["59 kDa dystrophin-associated protein A1 basic component 2","Syntrophin-3","SNT3","Syntrophin-like","SNTL"],"length_aa":540,"mass_kda":58.0,"function":"Adapter protein that binds to and probably organizes the subcellular localization of a variety of membrane proteins. May link various receptors to the actin cytoskeleton and the dystrophin glycoprotein complex. May play a role in the regulation of secretory granules via its interaction with PTPRN","subcellular_location":"Membrane; Cytoplasmic vesicle, secretory vesicle membrane; Cell junction; Cytoplasm, cytoskeleton","url":"https://www.uniprot.org/uniprotkb/Q13425/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SNTB2","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"UTRN","stoichiometry":10.0},{"gene":"SNX12","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/SNTB2","total_profiled":1310},"omim":[{"mim_id":"612540","title":"CONGENITAL MYOPATHY 12; CMYO12","url":"https://www.omim.org/entry/612540"},{"mim_id":"607456","title":"UTP4 SMALL SUBUNIT PROCESSOME COMPONENT; UTP4","url":"https://www.omim.org/entry/607456"},{"mim_id":"600027","title":"SYNTROPHIN, BETA-2; SNTB2","url":"https://www.omim.org/entry/600027"},{"mim_id":"600016","title":"CONTACTIN 1; CNTN1","url":"https://www.omim.org/entry/600016"},{"mim_id":"300632","title":"PDZ DOMAIN-CONTAINING 11; PDZD11","url":"https://www.omim.org/entry/300632"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Approved"},{"location":"Centriolar satellite","reliability":"Approved"},{"location":"Basal body","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Primary cilium transition zone","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SNTB2"},"hgnc":{"alias_symbol":["EST25263","SNT3"],"prev_symbol":["SNT2B2","SNTL","D16S2531E"]},"alphafold":{"accession":"Q13425","domains":[{"cath_id":"2.30.42.10","chopping":"113-203","consensus_level":"high","plddt":85.6064,"start":113,"end":203},{"cath_id":"2.30.29.30","chopping":"251-316_323-391_398-442","consensus_level":"medium","plddt":91.5483,"start":251,"end":442},{"cath_id":"2.30.29.30","chopping":"444-535","consensus_level":"high","plddt":92.7723,"start":444,"end":535}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13425","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13425-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13425-F1-predicted_aligned_error_v6.png","plddt_mean":78.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SNTB2","jax_strain_url":"https://www.jax.org/strain/search?query=SNTB2"},"sequence":{"accession":"Q13425","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13425.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13425/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13425"}},"corpus_meta":[{"pmid":"31558468","id":"PMC_31558468","title":"The whole-genome landscape of Burkitt lymphoma subtypes.","date":"2019","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/31558468","citation_count":141,"is_preprint":false},{"pmid":"8183929","id":"PMC_8183929","title":"Cloning of human basic A1, a distinct 59-kDa dystrophin-associated protein encoded on chromosome 8q23-24.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8183929","citation_count":121,"is_preprint":false},{"pmid":"2242259","id":"PMC_2242259","title":"Leiomyosarcoma of the sinonasal tract. A clinicopathologic study of nine cases.","date":"1990","source":"Archives of otolaryngology--head & neck surgery","url":"https://pubmed.ncbi.nlm.nih.gov/2242259","citation_count":58,"is_preprint":false},{"pmid":"30498476","id":"PMC_30498476","title":"Heritability and Genome-Wide Association Study of Plasma Cholesterol in Chinese Adult Twins.","date":"2018","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30498476","citation_count":18,"is_preprint":false},{"pmid":"25625330","id":"PMC_25625330","title":"Lipid abnormalities in alpha/beta2-syntrophin null mice are independent from ABCA1.","date":"2015","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25625330","citation_count":16,"is_preprint":false},{"pmid":"26617989","id":"PMC_26617989","title":"Individual protomers of a G protein-coupled receptor dimer integrate distinct functional modules.","date":"2015","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/26617989","citation_count":14,"is_preprint":false},{"pmid":"24465237","id":"PMC_24465237","title":"Characterization of H460R, a Radioresistant Human Lung Cancer Cell Line, and Involvement of Syntrophin Beta 2 (SNTB2) in Radioresistance.","date":"2013","source":"Genomics & informatics","url":"https://pubmed.ncbi.nlm.nih.gov/24465237","citation_count":13,"is_preprint":false},{"pmid":"25333956","id":"PMC_25333956","title":"Integrated analysis of microarray data of atherosclerotic plaques: modulation of the ubiquitin-proteasome system.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25333956","citation_count":10,"is_preprint":false},{"pmid":"30990585","id":"PMC_30990585","title":"Adipocyte Hypertrophy and Improved Postprandial Lipid Response in Beta 2 Syntrophin Deficient Mice.","date":"2019","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30990585","citation_count":8,"is_preprint":false},{"pmid":"10226653","id":"PMC_10226653","title":"Chromosomal sublocalization of the transcribed human telomere repeat binding factor 2 gene and comparative mapping in the mouse.","date":"1998","source":"Somatic cell and molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10226653","citation_count":7,"is_preprint":false},{"pmid":"30014220","id":"PMC_30014220","title":"The utrophin-beta 2 syntrophin complex regulates adipocyte lipid droplet size independent of adipogenesis.","date":"2018","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30014220","citation_count":6,"is_preprint":false},{"pmid":"26079703","id":"PMC_26079703","title":"Evaluation of the specificity of four commercially available antibodies to alpha-syntrophin.","date":"2015","source":"Analytical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26079703","citation_count":6,"is_preprint":false},{"pmid":"23860432","id":"PMC_23860432","title":"Adiponectin receptor 1 C-terminus interacts with PDZ-domain proteins such as syntrophins.","date":"2013","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23860432","citation_count":4,"is_preprint":false},{"pmid":"36999050","id":"PMC_36999050","title":"Clinical relevance of RNA editing profiles in lung adenocarcinoma.","date":"2023","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36999050","citation_count":1,"is_preprint":false},{"pmid":"36681100","id":"PMC_36681100","title":"Lower adiposity does not protect beta-2 syntrophin null mice from hepatic steatosis and inflammation in experimental non-alcoholic steatohepatitis.","date":"2023","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/36681100","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":10181,"output_tokens":2347,"usd":0.032874,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9509,"output_tokens":2551,"usd":0.05566,"stage2_stop_reason":"end_turn"},"total_usd":0.088534,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"SNTB2 (EST25263/basic A1 isoform) encodes a 59-kDa dystrophin-associated protein (DAP) that is part of the membrane cytoskeleton complex in muscle; it was isolated as a distinct syntrophin isoform and mapped to chromosome 16, establishing it as a component of the dystrophin-associated protein complex.\",\n      \"method\": \"cDNA cloning, partial peptide sequencing of purified DAP complex, EST database comparison, chromosomal mapping\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — protein purification and peptide sequencing identified the protein as a DAP complex member; single study but multiple orthogonal methods (biochemical purification, cloning, mapping)\",\n      \"pmids\": [\"8183929\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"SNTB2 binds to the α1D-adrenergic receptor (ADRA1D) through a C-terminal PDZ ligand interaction, ensuring receptor plasma membrane localization and G-protein coupling. Syntrophins (SNTA, SNTB1, SNTB2) did not interact with any of 22 other tested GPCRs containing Type I PDZ ligands, indicating specificity for ADRA1D.\",\n      \"method\": \"TAP/MS proteomic analysis, biochemical assays, dynamic mass redistribution analysis\",\n      \"journal\": \"Cell discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — TAP/MS plus dynamic mass redistribution, single lab, multiple orthogonal methods confirming PDZ-mediated interaction and functional consequence\",\n      \"pmids\": [\"26617989\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The C-terminus of adiponectin receptor 1 (AdipoR1) contains a class I PDZ-binding motif that interacts with SNTB2, identified by yeast two-hybrid screening of a liver library. However, AMPK and p38 MAPK phosphorylation downstream of AdipoR1 was not blocked in SNTB2-deficient mice, and AdipoR1 protein levels were normal in SNTB2 knockout mice, indicating SNTB2 is not required for AdipoR1 signaling or stability in liver.\",\n      \"method\": \"Yeast two-hybrid, PDZ-domain array, immunofluorescence colocalization, knockout mouse studies\",\n      \"journal\": \"Experimental and molecular pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — yeast two-hybrid and PDZ array identify interaction; functional consequence tested in KO mice by multiple readouts, single lab\",\n      \"pmids\": [\"23860432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SNTB2 expression is significantly upregulated in radioresistant H460R lung cancer cells; siRNA-mediated knockdown of SNTB2 sensitized H460, H460R, and H1299 cells to ionizing radiation, establishing a functional role for SNTB2 in radioresistance.\",\n      \"method\": \"Microarray gene expression profiling, siRNA knockdown, clonogenic survival assay, Western blot\",\n      \"journal\": \"Genomics & informatics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single siRNA knockdown approach with clonogenic assay; no mechanistic pathway placed\",\n      \"pmids\": [\"24465237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SNTB2 forms a protein complex with utrophin in adipocytes (co-immunoprecipitation). SNTB2 protein levels are strongly diminished when utrophin is knocked down. Knockdown of either utrophin or SNTB2 enhances lipid droplet (LD) growth during adipogenesis without affecting adipogenic transcription factors (C/EBPα, SREBP) or lipolysis, placing SNTB2 in a utrophin-dependent pathway that restrains LD expansion.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, lipid droplet size measurement, lipolysis assay, immunofluorescence localization\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal complex identified by Co-IP, functional consequence shown by KD with specific readout (LD size), single lab but multiple orthogonal methods\",\n      \"pmids\": [\"30014220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In adipocytes with SNTB2 knockdown, antilipolytic activity of insulin is enhanced (insulin more effectively suppresses lipolysis), while basal and stimulated lipolysis rates and Akt phosphorylation are normal, indicating SNTB2 modulates a specific arm of insulin signaling related to lipolysis suppression.\",\n      \"method\": \"siRNA knockdown, lipolysis assay, Western blot for phospho-Akt\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single knockdown method; limited mechanistic depth beyond the phenotypic observation\",\n      \"pmids\": [\"30014220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In fibroblasts, SNTB2 localizes to filamentous and vesicular structures that are distinct from beta-actin, alpha-tubulin, endoplasmic reticulum, early endosomes, lysosomes, and mitochondria, indicating a unique subcellular compartmentalization.\",\n      \"method\": \"Immunofluorescence colocalization in fibroblasts\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single immunofluorescence study, no functional consequence directly linked to localization\",\n      \"pmids\": [\"30014220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In alpha/beta2-syntrophin double-knockout (SNTA/B2-/-) mice, hepatic SR-BI protein is strongly reduced. This reduction is associated with increased phosphorylated ERK2 in liver, and pharmacological blockade of ERK activity upregulates SR-BI, indicating that SNTB2/SNTA loss elevates MAPK/ERK activity which in turn destabilizes SR-BI. Direct siRNA knockdown of SNTB2 alone in hepatocytes did not reduce SR-BI, suggesting the effect is indirect or requires combined loss of both syntrophins.\",\n      \"method\": \"Knockout mouse studies (DKO), ERK inhibitor treatment, siRNA knockdown in hepatocytes, Western blot\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout plus pharmacological intervention plus cell-based KD, multiple orthogonal methods; single lab\",\n      \"pmids\": [\"25625330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SNTB2-deficient mice on high-fat diet display reduced adiposity and adipocyte hypertrophy, with diminished caveolin-1 protein and collagen mRNA levels in white adipose tissue, enhanced fatty acid clearance in the fed state, and reduced systemic glucose. This places SNTB2 as a regulator of adipocyte size, caveolin-1 expression, and postprandial lipid metabolism in vivo.\",\n      \"method\": \"SNTB2 knockout mouse, high-fat diet challenge, histology, Western blot, serum metabolite measurements\",\n      \"journal\": \"Cellular physiology and biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo knockout with multiple metabolic and molecular readouts; single lab\",\n      \"pmids\": [\"30990585\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SNTB2 is a PDZ domain-containing scaffold/adaptor protein that is a component of the dystrophin-associated protein complex; it binds the α1D-adrenergic receptor C-terminal PDZ ligand to ensure plasma membrane localization and G-protein coupling, interacts with utrophin in adipocytes to restrain lipid droplet expansion, binds the AdipoR1 C-terminus (though this interaction is dispensable for AdipoR1 signaling in liver), regulates adipocyte size and caveolin-1 levels in vivo, modulates insulin's antilipolytic activity, and indirectly influences hepatic SR-BI stability through control of ERK activity, with additional evidence for a role in cellular radioresistance.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SNTB2 is a PDZ domain-containing syntrophin that acts as a membrane-associated scaffold/adaptor, originally identified as a 59-kDa component of the dystrophin-associated protein complex of the muscle membrane cytoskeleton [#0]. Through its PDZ domain it engages the C-terminal PDZ ligands of specific membrane receptors: it binds the \\u03b11D-adrenergic receptor (ADRA1D) to ensure receptor plasma membrane localization and G-protein coupling, with selectivity for ADRA1D over other PDZ-ligand GPCRs tested [#1], and it binds the C-terminus of adiponectin receptor 1 (AdipoR1), although this interaction is dispensable for AdipoR1 signaling and stability in liver [#2]. SNTB2 partners with utrophin in a complex that restrains lipid droplet expansion during adipogenesis, and its stability depends on utrophin [#4]. In vivo, SNTB2 regulates adipocyte size, caveolin-1 levels, and postprandial lipid and glucose metabolism [#8], and it shapes hepatic SR-BI abundance indirectly by limiting ERK/MAPK activity, an effect that requires combined loss of SNTB2 and \\u03b1-syntrophin [#7].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established the molecular identity of SNTB2 by showing it is a distinct syntrophin isoform belonging to the dystrophin-associated protein complex of the muscle membrane cytoskeleton.\",\n      \"evidence\": \"cDNA cloning, peptide sequencing of purified DAP complex, and chromosomal mapping\",\n      \"pmids\": [\"8183929\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not define the binding partners engaged by its PDZ domain\", \"No functional role assigned beyond complex membership\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Tested whether SNTB2's PDZ interaction with AdipoR1 is functionally required, addressing whether SNTB2 acts as a signaling adaptor for adiponectin signaling.\",\n      \"evidence\": \"Yeast two-hybrid liver library screen, PDZ-domain array, and knockout mouse readouts of AMPK/p38 phosphorylation\",\n      \"pmids\": [\"23860432\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The biological consequence of the AdipoR1\\u2013SNTB2 interaction outside liver is undefined\", \"No structural basis for the PDZ-ligand binding shown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Linked SNTB2 expression to a cellular phenotype by showing knockdown sensitizes lung cancer cells to radiation, implicating it in radioresistance.\",\n      \"evidence\": \"Microarray profiling, siRNA knockdown, and clonogenic survival assays in lung cancer lines\",\n      \"pmids\": [\"24465237\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No mechanistic pathway connecting SNTB2 to the DNA damage or survival response\", \"Single siRNA approach without rescue\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrated PDZ-ligand-specific recruitment of the \\u03b11D-adrenergic receptor by SNTB2, establishing a defined receptor-scaffolding function controlling receptor membrane localization and coupling.\",\n      \"evidence\": \"TAP/MS proteomics, biochemical binding assays, and dynamic mass redistribution analysis with a panel of 22 control GPCRs\",\n      \"pmids\": [\"26617989\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether other syntrophin-binding receptors exist in vivo is unresolved\", \"No structural model of the ADRA1D\\u2013SNTB2 PDZ interface\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Revealed an indirect role for SNTB2 in hepatic SR-BI stability via ERK control, distinguishing combined syntrophin loss from single-gene knockdown.\",\n      \"evidence\": \"\\u03b1/\\u03b22-syntrophin double-knockout mice, ERK inhibitor treatment, and hepatocyte siRNA knockdown with Western blot\",\n      \"pmids\": [\"25625330\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The molecular link between syntrophin loss and elevated ERK activity is not defined\", \"Functional redundancy with \\u03b1-syntrophin obscures the SNTB2-specific contribution\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Placed SNTB2 in a utrophin-dependent pathway restraining lipid droplet growth and identified a specific modulation of insulin's antilipolytic arm in adipocytes.\",\n      \"evidence\": \"Reciprocal Co-IP, siRNA knockdown, lipid droplet sizing, lipolysis assays, and phospho-Akt Western blot\",\n      \"pmids\": [\"30014220\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The mechanism by which the utrophin\\u2013SNTB2 complex limits lipid droplet expansion is unknown\", \"How SNTB2 selectively affects antilipolytic insulin signaling without altering Akt is unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined SNTB2 as an in vivo regulator of adipocyte size, caveolin-1 expression, and postprandial lipid/glucose metabolism under dietary challenge.\",\n      \"evidence\": \"SNTB2 knockout mice on high-fat diet with histology, Western blot, and serum metabolite measurements\",\n      \"pmids\": [\"30990585\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The direct molecular target linking SNTB2 to caveolin-1 levels is not identified\", \"Whether the metabolic phenotype derives from adipocyte-autonomous SNTB2 function is untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The unifying biochemical mechanism by which SNTB2's PDZ-mediated scaffolding controls receptor signaling, lipid droplet dynamics, and ERK activity across tissues remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural data on SNTB2 PDZ-ligand complexes\", \"No single signaling pathway unifies its adrenergic, adiponectin, and metabolic roles\", \"Tissue-specific contributions versus syntrophin redundancy not separated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 1, 2, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"complexes\": [\"dystrophin-associated protein complex\"],\n    \"partners\": [\"ADRA1D\", \"ADIPOR1\", \"UTRN\", \"SNTA1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":3,"faith_total":4,"faith_pct":75.0}}